Sipavibart (AZD-3152), a COVID-19 Pre-Exposure Prophylaxis in Myeloma Treated with BCMA/CD3 Bispecific Antibodies
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-208428
Abstract: Background. Bispecific antibodies BCMA/CD3 (BsAbs) increase the risk of developing infections related to the T-cell redirecting function in Multiple Myeloma (MM). Indeed, severe COVID-19 infections were observed despite repeated COVID-19 vaccine doses. COVID-19 targeting monoclonal… read more here.
Keywords: cd3 bsabs; covid; bcma cd3; treated bcma ... See more keywords
Validation and refinement of the new high-risk multiple myeloma (HRMM) criteria in relapsed or refractory patients treated with BCMA CAR-T.
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-2243
Abstract: Introduction: The consensus definition of high-risk multiple myeloma (HRMM) was recently revised by the International Myeloma Society (IMS) and International Myeloma Working Group (IMWG) to improve risk stratification in the era of contemporary therapies (Avet-Loiseau… read more here.
Keywords: hrmm; risk; bcma car; treated bcma ... See more keywords